Coave Therapeutics
Business Services · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
63bis Avenue Ledru Rolin, Paris, Ile-de-...Website
www.coavetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Coave Therapeutics
Coave Therapeutics formerly known as Horama, is a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases. The company is headquartered in Paris, France.Explore more
Coave Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Coave Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Coave Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Coave Therapeutics
Coave Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Coave Therapeutics recently announced quarterly report
Check if Coave Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Coave Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Coave Therapeutics has new funding data
Check out if Coave Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Coave Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Coave Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Coave Therapeutics.
Coave Therapeutics financials insights
Gather financial insights about Coave Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$35.1M
2021
Series B
$25M
2025
Series A
$32M
Coave Therapeutics Tech Stack
A closer look at the technologies used by Coave Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
New Hire
Executive Move
New Hire
Executive Move
Funding
Coave Therapeutics News & Media
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting being held 3-7 May 2026 in Denver, Colorado, as well as a company presentation at Eyecelerator @ ARVO on 1 May 2026.Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery
Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal deliveryCoave Therapeutics demonstrates superiority of its novel suprachoroidal capsid at ESGCT Congress 2025
PARIS, France – 7 October 2025: Coave Therapeutics (“Coave”), a company pioneering the future of genetic medicines, today announces that it will be presenting data on its lead suprachoroidal capsid, coAAV-SCS-01 in a poster at the European Society of Gene and Cell Therapy (EGSCT) Congress 2025, held from 7-10 October in Seville.Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
Paris, France – May 21, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board (SAB). This renewed SAB reflects Coave’s strategic shift from a platform-focused approach to the development of a therapeutic pipeline, as the Company advances multiple gene therapy programs. The SAB brings together internationally recognized leaders in adeno-associated viral (AAV) vector biology, gene therapy developmen
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Coave Therapeutics
Sign Up For FreeTo access detailed company insights
Coave Therapeutics formerly known as Horama, is a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare ocular and CNS (Central Nervous System) diseases. The company is headquartered in Paris, France.... Read More
